Avalo Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative therapies for rare and devastating diseases. The company utilizes its proprietary drug development platform to identify and advance treatments that target specific biological pathways, aiming to address unmet medical needs in various therapeutic areas. With a commitment to improving patient outcomes, Avalo works on a range of programs that include both preclinical and clinical-stage assets, striving to bring breakthrough solutions to market for patients with limited treatment options.
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results.
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow traded up 0.06% to 39,785.29 while the NASDAQ fell 0.13% to 16,383.85. The S&P 500 also rose, gaining, 0.10% to 5,253.70.
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
U.S. stocks traded slightly higher midway through trading, with the S&P 500 gaining around 0.1% on Thursday. The Dow traded up 0.06% to 39,785.87 while the NASDAQ rose 0.06% to 16,408.04. The S&P 500 also rose, gaining, 0.13% to 5,255.09.
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat quarterly earnings.
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.
Avalo Therapeutics shares are soaring after acquiring AVTX-009, a Phase 2-ready anti-IL-1β mAb. With $185 million in gross proceeds, Avalo aims to develop AVTX-009 for hidradenitis suppurativa and other chronic inflammatory indications. Chairman Garry Neil believes AVTX-009 holds immense potential in the multi-billion-dollar HS market.
